Endoscopic ultrasound (EUS) integrates an ultrasound transducer onto the tip of an endoscope to evaluate the gastrointestinal tract and surrounding retroperitoneal and mediastinal structures. By positioning the acoustic probe inside the lumen of the esophagus, stomach, or duodenum, EUS bypasses intervening bone, muscle, and subcutaneous fat. This proximity permits the use of higher ultrasound frequencies (5 to 12 MHz), yielding spatial resolution under 1 millimeter. The primary clinical goals of EUS include accurate TNM staging of gastrointestinal cancers, detailed characterization of subepithelial lesions, evaluation of pancreaticobiliary disorders, and EUS-guided tissue acquisition or therapeutic drainage.

Prior to the procedure, the patient is placed in the left lateral decubitus position. Topical pharyngeal anesthesia spray may be applied if upper EUS is performed under conscious sedation. Intravenous sedation or monitored anesthesia care (MAC) using propofol is initiated. The echoendoscope is introduced through the mouth (or anus for rectal EUS) and advanced under direct visual orientation into the organ of interest. High-frequency ultrasound transducers evaluate the wall layers and adjacent structures. When a target lesion or lymph node is identified, color Doppler imaging is applied to ensure no major vascular structures lie in the needle tract. Under real-time EUS guidance, a specialized 19-, 22-, or 25-gauge needle is advanced through the working channel into the target site. Multiple needle passes are made to acquire cellular aspirated material (FNA) or core tissue samples (FNB). Samples are deposited into preservative liquid or directly onto slides for cytological or pathological evaluation. Upon completion of ultrasound survey and tissue collection, the scope is slowly withdrawn, suctioning excess air or carbon dioxide.

Clinical benefits of EUS include superior diagnostic accuracy for small pancreatic lesions under 2 centimeters compared to cross-sectional CT or MRI, according to ASGE guidelines (2020). EUS provides precise micro-staging of GI tract cancers, reducing unnecessary exploratory surgery. The addition of fine-needle aspiration (EUS-FNA) or fine-needle biopsy (EUS-FNB) allows safe, real-time targeted tissue sampling through the gastrointestinal wall, achieving diagnostic sensitivity exceeding 90% for solid pancreatic masses (ESGE Guidelines 2021). Furthermore, EUS avoids exposure to ionizing radiation and intravenous contrast media required by computed tomography.

Recovery from diagnostic EUS is brief. Most patients awake within 15 to 30 minutes following procedure completion and meet discharge criteria within 1 to 2 hours. Mild sore throat, transient abdominal bloating, and slight fatigue from sedation are common for 24 hours. Patients may resume a normal soft diet and regular sedentary activities the day after the procedure. Normal non-strenuous routines resume within 24 to 48 hours. If EUS-guided tissue biopsy or therapeutic interventions were performed, patients are advised to avoid strenuous physical exertion and heavy lifting for 48 to 72 hours while monitoring for warning signs such as severe pain, fever, or bleeding.

Endoscopic ultrasound is utilized in the evaluation and staging of esophageal, gastric, duodenal, pancreatic, biliary, and rectal malignancies. It provides high-yield diagnostic assessment for solid pancreatic tumors, cystic pancreatic lesions, choledocholithiasis, chronic pancreatitis, enlarged mediastinal or abdominal lymph nodes of unknown origin, and subepithelial digestive lesions such as gastrointestinal stromal tumors (GISTs), leiomyomas, and neuroendocrine tumors. Therapeutically, EUS facilitates drainage of pancreatic fluid collections, pseudocysts, and obstructed biliary or pancreatic ducts.

Patients must maintain clear instructions regarding oral intake: solid foods must be avoided for at least 8 hours, and clear liquids must be stopped 2 hours prior to sedation, adhering to American Society of Anesthesiologists (ASA) fasting guidelines. Anticoagulant and antiplatelet medications (such as warfarin, clopidogrel, or direct oral anticoagulants) require temporary cessation or bridging based on individual cardiovascular risk and procedure risk stratification (ASGE/ESGE Hemostasis Guidelines 2021). Patients with diabetes must adjust insulin and oral hypoglycemic dosage in consultation with their treating physician. Routine diagnostic EUS does not require prophylactic antibiotics, but EUS-guided fine-needle aspiration of cystic pancreatic lesions requires prophylactic antibiotic administration to prevent cyst infection. Patients must arrange for a responsible adult driver to accompany them home following procedure discharge.

Diagnostic EUS without tissue acquisition carries a very low overall risk profile, with complication rates under 0.1%. When EUS-guided tissue acquisition (FNA/FNB) is performed, total complication rates range between 1% and 2% according to pooled clinical studies (ASGE Standards of Practice Committee 2020). Mild and common side effects include transient throat soreness, minor mucosal abrasions, mild post-procedure abdominal distension, and minor sedation-related lethargy. Less common complications (0.5% to 1.5%) include acute pancreatitis following pancreatic tissue sampling, post-procedure fever, and localized bacteremia. Rare but serious complications (under 0.5%) include gastrointestinal perforation, clinically significant intra-abdominal or intraluminal hemorrhage, cyst infection, and severe sedation-related respiratory depression or anaphylaxis.

The EUS clinical journey begins with a diagnostic evaluation, laboratory screening, and clinical assessment to establish indication and review contraindications. Patients fast for at least 6 to 8 hours prior to the procedure. On the day of EUS, conscious sedation or monitored anesthesia care is administered. The endoscopist advances the echoendoscope through the upper or lower digestive tract, performing detailed endosonographic mapping and tissue sampling if necessary. The active procedure typically lasts 30 to 60 minutes. After procedure completion, patients recover in a post-anesthesia unit for 1 to 2 hours before discharge. Preliminary visual findings are discussed immediately, while formal histopathological or cytopathological results from tissue biopsies follow within 3 to 7 business days during a planned follow-up consultation.